[go: up one dir, main page]

MX2019008911A - Metodos, matrices y usos de estos. - Google Patents

Metodos, matrices y usos de estos.

Info

Publication number
MX2019008911A
MX2019008911A MX2019008911A MX2019008911A MX2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
methods
determining
test sample
matrices
Prior art date
Application number
MX2019008911A
Other languages
English (en)
Inventor
Borrebaeck Carl
Wingren Christer
Dexlin Mellby Linda
Nyberg Andreas
Original Assignee
Immunovia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia Ab filed Critical Immunovia Ab
Publication of MX2019008911A publication Critical patent/MX2019008911A/es

Links

Classifications

    • G01N33/57525—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G01N33/575—
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención proporciona un método para diagnosticar o determinar un estado patológico asociado al cáncer de páncreas que comprende o consiste en las etapas de: (a) proporcionar una muestra de un individuo a analizar; y (b) determinar una firma de biomarcador de la muestra de prueba al medir la presencia y/o cantidad en la muestra de prueba de uno o más biomarcadores seleccionados del grupo definido en la Tabla A; en donde la presencia y/o cantidad en la muestra de prueba del uno o más biomarcadores seleccionados del grupo definido en la Tabla A es indicativa de la enfermedad asociada al cáncer de páncreas en el individuo; usos y métodos para determinar un estado patológico asociado al cáncer de páncreas, y métodos para tratar el cáncer de páncreas, junto con matrices y kits para usar en estos.
MX2019008911A 2017-01-31 2018-01-31 Metodos, matrices y usos de estos. MX2019008911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1701572.8A GB201701572D0 (en) 2017-01-31 2017-01-31 Methods, arrays and uses thereof
PCT/EP2018/052423 WO2018141804A1 (en) 2017-01-31 2018-01-31 Methods, arrays and uses thereof

Publications (1)

Publication Number Publication Date
MX2019008911A true MX2019008911A (es) 2019-09-26

Family

ID=58462729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008911A MX2019008911A (es) 2017-01-31 2018-01-31 Metodos, matrices y usos de estos.

Country Status (13)

Country Link
US (1) US20190382849A1 (es)
EP (1) EP3577464A1 (es)
JP (1) JP2020507760A (es)
KR (1) KR20190109422A (es)
CN (1) CN110325860A (es)
AU (1) AU2018214180A1 (es)
BR (1) BR112019015633A2 (es)
CA (1) CA3051968A1 (es)
GB (1) GB201701572D0 (es)
IL (1) IL268244A (es)
MX (1) MX2019008911A (es)
RU (1) RU2019123695A (es)
WO (1) WO2018141804A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107102142A (zh) * 2007-03-27 2017-08-29 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
JP2022537672A (ja) 2019-07-03 2022-08-29 クリスタル バイオサイエンス インコーポレイテッド 抗ｂ７－ｈ３抗体およびその使用方法
KR102289278B1 (ko) * 2019-07-09 2021-08-13 주식회사 베르티스 췌장암 진단용 바이오마커 패널 및 그 용도
JP2023507369A (ja) * 2019-12-20 2023-02-22 メディミューン，エルエルシー グリピカン３を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CA3214598A1 (en) * 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用
CN120177800B (zh) * 2025-05-23 2025-10-10 四川大学 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US8632983B2 (en) * 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
CN107102142A (zh) 2007-03-27 2017-08-29 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
WO2012031374A1 (zh) * 2010-09-09 2012-03-15 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及其单克隆抗体
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Also Published As

Publication number Publication date
RU2019123695A (ru) 2021-03-02
IL268244A (en) 2019-09-26
CN110325860A (zh) 2019-10-11
BR112019015633A2 (pt) 2020-03-17
GB201701572D0 (en) 2017-03-15
EP3577464A1 (en) 2019-12-11
US20190382849A1 (en) 2019-12-19
JP2020507760A (ja) 2020-03-12
KR20190109422A (ko) 2019-09-25
WO2018141804A1 (en) 2018-08-09
CA3051968A1 (en) 2018-08-09
AU2018214180A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2019008911A (es) Metodos, matrices y usos de estos.
MX2018013621A (es) Metodo, matriz y uso de estos.
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
BR112017007965A8 (pt) Método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX373248B (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX2017003790A (es) Detección de secuencias diana por percepción de nanoporos de sondas sintéticas.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
CL2017001972A1 (es) Biomarcadores para cáncer pancreático
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
BR112018015965A2 (pt) método para determinação de helicobacter pylori
BR112018009463A2 (pt) ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
BR112016017926A2 (pt) ensaio para detectar periostina humana
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
BR112016029562A2 (pt) métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos